ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease...(ion software. ActiveSight has leveraged ...),Health

Date:9/18/2007

ion software. ActiveSight has leveraged these capabilities to screen several drug targets with their proprietary fragment libraries, and is pursuing lead development on promising fragment hits. The CHDI project will be overseen by Vicki Nienaber, Ph.D. at ActiveSight, a pioneer in the utilization of X-ray crystallography for Fragment-based screening and lead development.

"We are pleased to have the opportunity to work with CHDI to discover new treatments for Huntington Disease," said Duncan McRee, Ph.D., President of ActiveSight. "We will work closely with CHDI's drug discovery team to turn the results of our high-throughput FBLD screens into tightly binding lead compounds."

About Huntington Disease

Huntington Disease is a familial disease, passed from parent to child through a mutation in a gene. Each child of a Huntington Disease parent has a 50-50 chance of inheriting the Huntington Disease gene which causes programmed degeneration of brain cells and results in emotional disturbance, loss of intellectual faculties and uncontrolled movements. Most people with Huntington Disease develop the symptoms at midlife but in some people onset occurs in infancy or old age. The average survival time after onset is approximately fifteen to twenty years. It is estimated that about one in every 10,000 persons has the Huntington Disease gene. At this time, there is no way to stop or reverse the course of Huntington Disease.

About ActiveSight

ActiveSight(R) is a division of Rigaku Americas Corporation and is a leading provider of fragment-based lead discovery and structural biology for drug discovery. Utilizing high-throughput Rigaku X-ray crystallography instrumentation and world-class expertise, ActiveSight enables rapid lead discovery and development for its pharmaceutical, biotechnology, and institutional partners. For more information visit http://www.active-sight.com.

About CHDI, Inc
'/>"/>

SOURCE ActiveSight Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric Academic Societies Annual Meeting
4. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
5. Clinical Trial Results Suggest Long-Term Treatment Benefit of Tetrabenazine for Chorea Associated with Huntingtons Disease
6. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
7. Appendicitis: Evolving Tools to Diagnose a Classic Disease
8. Non-Invasive Diagnostic Tests for Celiac Disease
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease